TTNP (Titan Pharmaceuticals) YoY EBITDA Growth: 72.77% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTNP Titan Pharmaceuticals Inc TTNP
9 GF Score
Price $4.61
View Full Analysis

What is Titan Pharmaceuticals YoY EBITDA Growth?

Titan Pharmaceuticals TTNP 9 YoY EBITDA Growth is 72.77% as of Jun. 2025. GuruFocus rates TTNP with a GF Score™ of 9/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Titan Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2025 was 72.77%.

Titan Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2025 was $-0.62.

Titan Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Titan Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals YoY EBITDA Growth Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.40 49.79 20.34 36.22 46.86

Titan Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.84 69.53 71.46 53.05 72.77
TTNP
9GF Score
Titan Pharmaceuticals Inc TTNP
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Titan Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-5.063--9.528)/ | -9.528 |
=46.86 %

Titan Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (Q: Jun. 2025 )
=(EBITDA per Share (Q: Jun. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.617--2.266)/ | -2.266 |
=72.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 72.77% mean?
Titan Pharmaceuticals (TTNP) has a YoY EBITDA Growth of 72.77% as of Jun. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Titan Pharmaceuticals and its competitors.
Is Titan Pharmaceuticals' YoY EBITDA Growth too high?
Titan Pharmaceuticals' current YoY EBITDA Growth is 72.77%. Overall, Titan Pharmaceuticals has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Titan Pharmaceuticals' YoY EBITDA Growth compare to TCRT and SXTP?
Titan Pharmaceuticals' YoY EBITDA Growth of 72.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Titan Pharmaceuticals and its competitors. Titan Pharmaceuticals's current YoY EBITDA Growth is 72.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Pharmaceuticals stock overvalued right now?
Titan Pharmaceuticals (TTNP) has a current YoY EBITDA Growth of 72.77%. The current YoY EBITDA Growth is 72.77%. Titan Pharmaceuticals' overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Titan Pharmaceuticals (TTNP), the current YoY EBITDA Growth is 72.77% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Titan Pharmaceuticals Business Description

Address 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
9GF Score

Get the complete analysis for TTNP

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price